Drug updated on 9/4/2024
Dosage Form | Cream (topical; 1%) |
Drug Class | Aryl hydrocarbon receptor agonists |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the topical treatment of plaque psoriasis in adults.
Latest News
Summary
- Vtama (tapinarof) is indicated for the topical treatment of plaque psoriasis in adults.
- This summary is based on the review of five systematic review(s)/meta-analysis(es). 3. 1% tapinarof cream demonstrated superior effectiveness in treating psoriasis compared to placebo with Odds Ratios (OR) of 8.3 (95% CI: 5.5, 13.0) at 4 weeks, 8.3 (95% CI: 5.9, 13.0) at 8 weeks, and 7.3 (95% CI: 5.1, 11.0) at 12 weeks. It was also superior to calcipotriol, though specific OR values were not provided. [1-5]
- Benvitimod significantly improved multiple psoriasis outcomes compared to placebo, including a Physician Global Assessment (PGA) score of 0 or 1 (Relative Risk [RR] = 6.53, 95% CI: 4.39, 9.71), PASI 75 (RR = 4.34, 95% CI: 2.96, 6.36), and PASI 90 (RR = 8.83, 95% CI: 5.22, 14.95).
- For atopic dermatitis, tapinarof, crisaborole, and ruxolitinib led to statistically significant improvements in disease severity scores, while ARQ-151 cream achieved statistical significance in secondary endpoints, such as vIGA-AD and EASI-75, but not in the primary endpoint.
- The incidence of adverse events was higher for 1% tapinarof cream compared to placebo (OR = 3.3, 95% CI: 2.6, 4.3) and calcipotriol; no serious systemic adverse events were reported.
- Benvitimod showed a higher incidence of adverse events compared to placebo (RR = 1.98, 95% CI: 1.73, 2.27); the risk for serious adverse events was non-significant.
- Tapinarof, crisaborole, ARQ-151 cream, and ruxolitinib were well-tolerated by study participants, with no serious safety concerns highlighted.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Vtama (tapinarof) Prescribing Information. | 2022 | Dermavant Sciences Inc., Long Beach, CA |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
1% Tapinarof cream for the treatment of psoriasis: a network meta-analysis of randomized placebo- and calcipotriol- controlled trials. | 2023 | Archives of Dermatological Research |
Benvitimod for the treatment of psoriasis: a systematic review and meta-analysis of randomized controlled trials. | 2022 | Dermatologic Therapy |
Application of benvitimod on psoriasis: a systematic review and meta-analysis of randomized controlled trials. a systematic review of benvitimod. | 2022 | Therapies |
New treatments in atopic dermatitis. | 2021 | Annals of Allergy, Asthma & Immunology |
Topical agents currently in phase II or phase III trials for atopic dermatitis. | 2020 | Journal of Drugs in Dermatology |
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: a novel topical therapy targeting the aryl hydrocarbon receptor. | 2023 | Journal of Managed Care & Specialty Pharmacy |